DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for disease of bone structure — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDisease of bone structure maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for disease of bone structure is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1929 case report described an undescribed bone disease, but no specific drug or treatment was proposed. By 1971, a review of osteoporosis stated that existing therapies were "inadequately evaluated and often disappointing" and that controlled, prospective clinical trials were needed even as the search continued for better methods of inhibiting bone resorption or stimulating bone formation. A 2001 review noted that genomics had identified many genes involved in bone formation and remodelling, including those linked to achondroplasia, Crouzon syndrome, and Ellis-van Creveld syndrome, but it reviewed prevention and treatment modalities without reporting any new drug efficacy data.
A 2017 review reported that new drugs were moving through the osteoporosis pipeline, with one having "fallen by the wayside at the last hurdle," and that a "treatment gap" persisted between patients who would benefit and those actually receiving treatment. Tangible developments were noted for some rare bone and calcium diseases, but no specific drug names or response rates were given. A 2020 review described rare bone formation disorders such as sclerosteosis, van Buchem disease, hypophosphatasia, and Camurati-Engelmann disease, and stated that identifying the molecular defects behind these diseases could open the way for new therapeutic approaches for common bone diseases including osteoporosis. A 2025 review of osteoclast-related diseases stated that identifying specific gene mutations as potential therapeutic targets would be an important step toward future personalised gene therapies.
No clinical trial results, survival rates, or response rates for any drug are reported in any of these abstracts. The 1971 review explicitly calls the existing therapies disappointing. What is still missing are adequately powered, controlled prospective trials for existing treatments, a clear strategy to close the treatment gap between eligible and treated patients, and the translation of identified gene mutations into validated, personalised therapies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Endocrinology · 2020 · 6 citations · open access
Looking for new anabolic treatment from rare diseases of bone formation
AbstractBone remodelling is a complex mechanism regulated by osteoclasts and osteoblasts and perturbation of this process leads to the onset of diseases, which may be characterised by altered bone erosion or formation. In this review, we will describe some bone formation-related disorders as sclerosteosis, van Buchem disease, hypophosphatasia and Camurati-Engelmann disease. In the past decades, the research focused on these rare disorders offered the opportunity to understand important pathways regulating bone formation. Thus, the identification of the molecular defects behind the etiopathology of these diseases will open the way for new therapeutic approaches applicable also to the management of more common bone diseases including osteoporosis.
AbstractThe questions raised by this complex group of diseases are many, the answers few, and the existing therapies inadequately evaluated and often disappointing. Despite our imperfect understanding of pathogenesis, the available treatment regimens deserve controlled, prospective clinical trials even as the search continues for better methods of inhibiting bone resorption and/or stimulating bone formation.
Bone Disease - Current Knowledge and Future Prospects
AbstractThe advent of genomics approaches to studying human disease have yielded a large number of genes and gene families that are involved in the process of bone formation and bone remodeling. The identification and characterization of these genes has provided significant insights into the pathogenesis of numerous human bone diseases. This review details current understanding of the role of many of these genes in bone development and disease. We review the current status of bone disease prevention/treatment modalities and describe how recent advances in our understanding of the molecules responsible for different aspects of osteoblast, osteoclast and chondrocyte function may provide novel biochemical markers and treatment strategies for bone disease. Keywords: Bone Disease, Aromatase Deficieny, linked dominant Conradi-Hunermann, Down Syndrome skeletal abnormalities, Ellis-van Creveld syndrome, Crouzon syndrome, Apert syndrome, Pfeiffer syndrome, multiple epiphyseal dysplasia (MED), achondroplasia
touchREVIEWS in Endocrinology · 2017 · 1 citations · open access
Progress and Problems in Bone and Mineral Disorders
AbstractA number of new drugs are moving through the osteoporosis therapy pipeline. Some show great promise for patients while one has fallen by the wayside at the last hurdle. New, effective therapies are warmly welcomed but there are still uncertainties around management of osteoporosis with currently available drugs that are contributing to what is commonly being referred to as the 'treatment gap'; a differential between those patients who would benefit from treatment versus those who actually are receiving it. Furthermore, in parallel to the common public health disease of osteoporosis, there have been tangible developments in therapies available for some rare bone and calcium diseases.
Mutations in Osteoclast Genes as Causes of Osteoclast-Related Diseases
AbstractOsteoclasts, as the only cells capable of resorbing bone, play a significant role in all processes that take place at the level of bone tissue and are involved in the development of the skeleton, maintenance of its integrity, repair, and regeneration of bones. Therefore, it is not surprising that even small deviations from their normal functioning result in diseases that not only affect skeletal system but also the entire organism. There are a number of rare genetic bone diseases associated with mutations in osteoclast genes that govern their differentiation and function. Specifically, they are known as osteoclast-related diseases, and their main hallmark is either decreased or increased bone resorption. To understand the impact of osteoclast gene mutations on the course of these diseases, it is also necessary to know the cellular and molecular mechanisms underlying osteoclast development and function. Moreover, identification of specific gene mutations as potential therapeutic targets would be an important step in creating personalized gene therapies in the future.
AbstractJournal Article An undescribed disease of bone Get access J H Sheldon J H Sheldon Hon, Physician The Wolverhampton and Staffordshire Hospital Search for other works by this author on: Oxford Academic Google Scholar British Journal of Surgery, Volume 16, Issue 63, January 1929, Pages 405–430, https://doi.org/10.1002/bjs.1800166306 Published: 05 December 2005
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
